US OptionsDetailed Quotes
URGN250516P15000
- 5.60
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
5.60Open5.60Pre Close0 Volume78 Open Interest15.00Strike Price0.00Turnover175.51%IV18.33%PremiumMay 16, 2025Expiry Date3.49Intrinsic Value100Multiplier12DDays to Expiry2.11Extrinsic Value100Contract SizeAmericanOptions Type-0.7476Delta0.0872Gamma2.91Leverage Ratio-0.0476Theta-0.0036Rho-2.18Eff Leverage0.0067Vega
UroGen Pharma Ltd Stock Discussion
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients
Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations
No comment yet